Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Authors
Keywords
Glioblastoma, Anti-angiogenesis, MRI, Progression-free survival, Overall survival, Tivozanib
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 131, Issue 3, Pages 603-610
Publisher
Springer Nature
Online
2016-11-17
DOI
10.1007/s11060-016-2332-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies
- (2015) Corina N. Oldenhuis et al. Clinical Colorectal Cancer
- Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- (2015) Christine Lu-Emerson et al. JOURNAL OF CLINICAL ONCOLOGY
- Neural network alterations underlie cognitive deficits in brain tumor patients
- (2014) Jolanda Derks et al. CURRENT OPINION IN ONCOLOGY
- Comparative Evaluation of Registration Algorithms in Different Brain Databases With Varying Difficulty: Results and Insights
- (2014) Yangming Ou et al. IEEE TRANSACTIONS ON MEDICAL IMAGING
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
- (2014) Kyrre E. Emblem et al. Nature Reviews Clinical Oncology
- Modern network science of neurological disorders
- (2014) Cornelis J. Stam NATURE REVIEWS NEUROSCIENCE
- A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
- (2013) Erica L. Mayer et al. BREAST CANCER RESEARCH AND TREATMENT
- Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI
- (2013) Robert J. Harris et al. JOURNAL OF NEURO-ONCOLOGY
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
- (2013) Kyrre E Emblem et al. NATURE MEDICINE
- Local MEG networks: The missing link between protein expression and epilepsy in glioma patients?
- (2013) L. Douw et al. NEUROIMAGE
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set
- (2013) David A. Gutman et al. RADIOLOGY
- Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
- (2012) Dmitry A. Nosov et al. JOURNAL OF CLINICAL ONCOLOGY
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
- (2011) F. A. L. M. Eskens et al. CLINICAL CANCER RESEARCH
- On the scope and interpretation of the Tofts models for DCE-MRI
- (2011) Steven P. Sourbron et al. MAGNETIC RESONANCE IN MEDICINE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
- (2010) D. G. Duda et al. ONCOLOGIST
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now